The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice
Open accessAbstract
Liver X receptors (LXRα and LXRβ) are important regulators of cholesterol and lipid metabolism, and their activation has been shown to inhibit cardiovascular disease and reduce atherosclerosis in animal models. Small molecule agonists of LXR activity are therefore of great therapeutic interest. However, the finding that such agonists also promote hepatic lipogenesis has led to the idea that hepatic LXR activity is undesirable from a therapeutic perspective. To investigate whether this might be true, we performed gene targeting to selectively delete LXRα in hepatocytes. Liver-specific deletion of LXRα in mice substantially decreased reverse cholesterol transport, cholesterol catabolism, and cholesterol excretion, revealing the essential importance of hepatic LXRα for whole body cholesterol homeostasis. Additionally, in a pro-atherogenic background, liver-specific deletion of LXRα increased atherosclerosis, uncovering an important function for hepatic LXR activity in limiting cardiovascular disease. Nevertheless, synthetic LXR agonists still elicited anti-atherogenic activity in the absence of hepatic LXRα, indicating that the ability of agonists to reduce cardiovascular disease did not require an increase in cholesterol excretion. Furthermore, when non-atherogenic mice were treated with synthetic LXR agonists, liver-specific deletion of LXRα eliminated the detrimental effect of increased plasma triglycerides, while the beneficial effect of increased plasma HDL was unaltered. In sum, these observations suggest that therapeutic strategies that bypass the liver or limit the activation of hepatic LXRs should still be beneficial for the treatment of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 1×
“Upregulation of ABCA1 and ABCG1 results in increased transfer of intracellular cholesterol to HDL particles, and genome-wide association studies have linked both transporters to HDL cholesterol levels in humans (5, 6).”
The Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069 · cited 1×
“The parallel arm in the pathway leads to synthesis of muricholic acid (MCA) in mice and chenodeoxycholic acid (CDCA) in humans (42).”
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233 · cited 1×
“The regulation of bile acid synthesis by LXR has also been suggested to contribute to the ability of LXR agonists to dispose of cholesterol (22, 41).”
Self-citationHDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Murphy, A. J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.-L., Wang, M., Sanson, M., Abramowicz, S., Welch, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57559 · Cited by 521
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo
Brunham, L. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27352 · Cited by 519
Timmins, J. M., Lee, J.-Y., Boudyguina, E., Kluckman, K. D., Brunham, L. R., Mulya, A., Gebre, A. K., Coutinho, J. M., Colvin, P. L., Smith, T. L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23915 · Cited by 447
Brunham, L. R., Kruit, J. K., Pape, T. D., Parks, J. S., Kuipers, F., & Hayden, M. R. (2006) · Circulation Research · doi:10.1161/01.res.0000244014.19589.8e · Cited by 118
Bischoff, E. D., Daige, C. L., Petrowski, M., Dedman, H., Pattison, J., Juliano, J., Li, A. C., & Schulman, I. G. (2010) · The Journal of Lipid Research · doi:10.1194/jlr.m900096 · Cited by 91 · cited 8×
“Previous studies with global knockouts demonstrated that LXRα is a major regulator of hepatic SREBP-1c expression and triglyceride levels (15, 24).”
InfluentialSelf-citation
Cited by
Liver X receptors in lipid signalling and membrane homeostasis
Wang, B., & Tontonoz, P. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0037-x · Cited by 722
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss
Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523
“Liver triglyceride and cholesterol levels were measured as described (Zhang et al., 2012).”
Self-citation27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth
Wu, Q., Ishikawa, T., Sirianni, R., Tang, H., McDonald, J. G., Yuhanna, I. S., Thompson, B., Girard, L., Mineo, C., Brekken, R. A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.006 · Cited by 358
Transcriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP
Xu, X., So, J.-S., Park, J.-G., & Lee, A.-H. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358523 · Cited by 308
The Transcription Factor ZEB2 Is Required to Maintain the Tissue-Specific Identities of Macrophages
Scott, C. L., T’Jonck, W., Martens, L., Todorov, H., Sichien, D., Soen, B., Bonnardel, J., De Prijck, S., Vandamme, N., Cannoodt, R., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.004 · Cited by 299
Bile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00517.x · Cited by 279
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
Phenotypic Polarization of Macrophages in Atherosclerosis
Leitinger, N., & Schulman, I. G. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300173 · Cited by 256
Self-citationLiver X receptors link lipid metabolism and inflammation
Schulman, I. G. (2017) · FEBS Letters · doi:10.1002/1873-3468.12702 · Cited by 244
Self-citationFeedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis
Sallam, T., Jones, M. C., Gilliland, T., Zhang, L., Wu, X., Eskin, A., Sandhu, J., Casero, D., Vallim, T. Q. D. A., Hong, C., et al. (2016) · Nature · doi:10.1038/nature17674 · Cited by 212
Paniagua, J. A. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i19.483 · Cited by 197
Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion
Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., et al. (2022) · Nature · doi:10.1038/s41586-022-05006-3 · Cited by 188
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
Fessler, M. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.010 · Cited by 173
Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Self-citationNuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
“However, LXR at the same time promotes cholesterol efflux, reduces cholesterol synthesis and uptake [161,187].”
BackgroundRamadori, P., Drescher, H., Erschfeld, S., Schumacher, F., Berger, C., Fragoulis, A., Schenkel, J., Kensler, T. W., Wruck, C. J., Trautwein, C., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.014 · Cited by 61
Zhang, Y., Jiang, X., Wang, W., Lei, L., Sheng, R., Li, S., Luo, J., Liu, H., Zhang, J., Han, X., et al. (2024) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.124.321076 · Cited by 27
Self-citationFima, R., Dussaud, S., Benbida, C., Blanchet, M., Lanthiez, F., Poupel, L., Brambilla, C., Gélineau, A., Dessena, M., Blanc, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52735-2 · Cited by 14
Lee, N. Y., Choi, M. G., Ryu, H. J., Min, Y. J., Kim, S. M., Chung, Y., Koo, B. K., Kang, Y. P., Kim, W., & Koo, J. H. (2026) · Advanced Science · doi:10.1002/advs.202500379 · Cited by 2
Metadata
- Authors
- Zhang, Y., Breevoort, S. R., Angdisen, J., Fu, M., Schmidt, D. R., Holmstrom, S. R., Kliewer, S. A., Mangelsdorf, D. J., & Schulman, I. G.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-05-01
- Volume
- 122
- Issue
- 5
- Pages
- 1688-1699
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2141256126
- Cited by
- 213
- References
- 9
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.